Monoclonal Antibody News, Research, Oct 27, 2010

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Morphotek receives DOD contract to support mAb therapies against pathogenic strains

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Researchers discover link between hereditary and sporadic ALS

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy